Empagliflozin for Arterial Health in Obese Veterans

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Recruiting Phase 2 Interventional Study
Obesity Vascular Health
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 – 60
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
VA Office of Research and Development · Federal
Who this trial is looking for

This trial is looking for veterans with obesity to see how a medication called empagliflozin affects their arterial health. Participants will take either the medication or a placebo for 12 weeks.

Are You a Good Fit for This Trial?
Must not be taking GLP-1 analogsSGLT2 inhibitorsHormone replacement therapyWeight loss medicationsAnticoagulants
Rules you out Heart failureIschemic heart diseasePeripheral artery diseaseStrokeKetoacidosisRecurrent UTIsMycotic genital infections

You may be able to join if

  • I have a body mass index (BMI) of 30-45.
  • I am 30-60 years old.
  • I have evidence of arterial stiffening.

You may not be able to join if

  • I cannot provide consent.
  • I have diabetes.
  • I have uncontrolled high blood pressure.
  • I have a history of heart disease or stroke.
  • I have chronic kidney disease.
  • I have active cancer.
  • I drink excessive alcohol.
  • I am pregnant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Body mass index (BMI) 30-45 kilograms per square meter (kg/m2) * 30-60 years of age at randomization * Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030), or presence of Stage I hypertension or higher (PMID: 3035…
Contacts

Jaume Padilla Parellada, PhD

(573) 814-6552

jaume.padillaparellada@va.gov

CONTACT

Camila Margarita M Manrique Acevedo, MD

(573) 814-6550

camila.manrique-acevedo@va.gov

CONTACT